Generic Semaglutide Pricing Could Disrupt Global Markets

New research reveals that manufacturers could sell generic versions of Novo Nordisk’s blockbuster drugs, Ozempic and Wegovy, for less than $3 a month. This study highlights a massive gap between current list prices and actual production costs. It suggests a future where powerful weight-loss treatments are accessible to billions. The Massive Gap In Generic Semaglutide Pricing Researchers at the University…

Continue reading with a Health Matters subscription

Subscribers read every article in full, receive the daily briefing and have access to the complete archive.

SubscribeLog in